Arihanta Siddha Laboratories Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 23-12-2024
- Paid Up Capital ₹ 0.31 M
as on 23-12-2024
- Company Age 37 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.37 Cr
as on 23-12-2024
- Satisfied Charges ₹ 4.39 M
as on 23-12-2024
- Revenue -32.23%
(FY 2023)
- Profit -49.94%
(FY 2023)
- Ebitda -11.67%
(FY 2023)
- Net Worth 3.94%
(FY 2023)
- Total Assets -1.86%
(FY 2023)
About Arihanta Siddha Laboratories
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.31 M.
The company currently has active open charges totaling ₹1.37 Cr. The company has closed loans amounting to ₹4.39 M, as per Ministry of Corporate Affairs (MCA) records.
Nilesh Dorle and Prasad Dorle serve as directors at the Company.
- CIN/LLPIN
U24239PN1987PTC044408
- Company No.
044408
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Aug 1987
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Sangli, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Arihanta Siddha Laboratories?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nilesh Dorle  | Director | 01-Sep-2000 | Current |
| Prasad Dorle | Director | 24-Jan-2013 | Current |
Financial Performance of Arihanta Siddha Laboratories.
Arihanta Siddha Laboratories Pvt Ltd, for the financial year ended 2023, experienced significant reduction in revenue, with a 32.23% decrease. The company also saw a substantial fall in profitability, with a 49.94% decrease in profit. The company's net worth moved up by a moderate rise of 3.94%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Arihanta Siddha Laboratories?
In 2023, Arihanta Siddha Laboratories had a public holding of 8.09%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 09 Jul 2015 | ₹6.66 M | Open |
Hdfc Bank Limited Creation Date: 02 May 2015 | ₹6.66 M | Open |
The Maharashtra State Financial Corporation Creation Date: 06 Nov 1989 | ₹0.40 M | Open |
How Many Employees Work at Arihanta Siddha Laboratories?
Unlock and access historical data on people associated with Arihanta Siddha Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Arihanta Siddha Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Arihanta Siddha Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
